DentalMonitoring Sets New Standard In Orthodontic Remote Monitoring With De Novo Approval By the U.S. Food and Drug Administration (FDA).
DentalMonitoring®, the leader in AI-powered remote monitoring for orthodontic treatment, has received De Novo approval from the U.S. Food and Drug Administration (FDA) for the DentalMonitoring solution to be used by orthodontists in optimizing clinical care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520240852/en/
DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring with De Novo Approval by the U.S. Food and Drug Administration (FDA) (Graphic: Business Wire)
DentalMonitoring is a medical device software using image processing algorithms to analyze pictures of the oral cavity (hereinafter Scans). Scans are taken using the DM App, a smartphone, and the manufacturer’s proprietary hardware products. DentalMonitoring is indicated for use for patients over the age of 6 and reports results solely on permanent teeth.
The product is designed to assist healthcare professionals in remotely monitoring dental treatments, orthodontic treatments, oral health, and treatment progress. The results of DentalMonitoring are intended to be used as an aid in diagnosis and not on a stand-alone basis for clinical decision-making.
DentalMonitoring provides additional information compared to traditional orthodontic treatment follow-up. DentalMonitoring is an additional asset to ensure patient compliance to orthodontic treatment requirements. With DentalMonitoring, clinicians enjoy an elevated level of insight into treatment progress while patients enjoy increased convenience. Automated notifications and in-app communication with practice staff increase patient accountability and enhance communication between patients, healthcare providers, and caregivers.
With this approval, DentalMonitoring will also introduce the innovative SmartSTL™ feature to North American orthodontist customers. SmartSTL allows doctors to request updated STL files via the DentalMonitoring dashboard without bringing the patient back into the office.
“We are proud to be the new standard of care in orthodontics. This is a recognition of our 10 years of research and development in Deep Learning Artificial Intelligence. FDA approval of this improved version of DentalMonitoring software is a key milestone for DentalMonitoring and marks the beginning of a new era in orthodontics,” says Philippe Salah, CEO and co-founder of DentalMonitoring.
Since 2012, only four De Novos have been granted by the FDA Dental panel, and none were software-based devices. DentalMonitoring is the first Artificial Intelligence/Machine Learning-enabled Software as a Medical Device in dentistry, establishing a classification within FDA dental regulation numbers and product codes. With the grant of this De Novo and the creation of a new regulatory category, DentalMonitoring has paved the way for future innovations in the Software as a Medical Device in the dental field category.
This clearance is a result of Dental Monitoring’s investment in pushing digital health technologies to the forefront of dental care. DentalMonitoring’s innovation has benefited users with elevated clinical outcomes and increased their peace of mind.
About DentalMonitoring:
DentalMonitoring is transforming orthodontic care globally through our advanced AI-driven platform. Our mission is to empower orthodontic practitioners with precise, real-time treatment monitoring and decision-making tools. By enhancing the connection between clinicians and patients, we make it possible to optimize treatment outcomes and ensure high-quality, efficient, and personalized orthodontic experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520240852/en/
Contact information
Celine Cendras-White
Head of Marketing Communication
+33 18 695 0101
public-relations@dental-monitoring.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two Young Chefs Have Passed the Japanese Cuisine Certification Exam (Organized by JCDC) and Have Newly Acquired Gold Certification!21.3.2025 15:00:00 CET | Press Release
The Japanese Cuisine and Dietary Culture Development Committee (JCDC) (Location: Minato-ku, Tokyo; Representative: Yoshihiro Murata; Website: https://en.jcdc.tokyo/), which supports and promotes the spread of Japanese food overseas, held a certification exam for foreign chefs in Kyoto. This certification exam is based on the “Guidelines for Certification of Cooking Skills for Japanese Cuisine in Foreign Countries” (enacted on April 1, 2016 / revised on April 1, 2024) established by the Ministry of Agriculture, Forestry and Fisheries (MAFF) of Japan. In this examination, two people from Vietnam, Le Minh Tien and Pham Duc Duy, successfully obtained Gold certification. In addition, the two foreign chefs who came to Japan to participate in the Kyoto final of the “Road to Japanese Culinary Arts Award 2024-2025” hosted by the Japanese Culinary Academy were also certified as Silver. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025
DEWA’s General Assembly Approves Dividend Payment of AED 3.1 Billion to Shareholders for H2 of 202421.3.2025 14:34:00 CET | Press Release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), reported that its shareholders have, in the general assembly held on 21 March 2025, approved the payment of total dividend of AED 3.1 billion for H2 of 2024, with a record date of 31 March 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250321365368/en/ During DEWA’s General Assembly (Photo: AETOSWire) The meeting, chaired by HE Matar Humaid Al Tayer, Chairman of the Board of Directors of DEWA, was attended by HE Saeed Mohammed Al Tayer, MD & CEO of DEWA, and Members of the Board of Directors of DEWA as well as 92.2% of the shareholders. During the meeting, a Board of Directors was elected for the next three years. For shareholders who are invested in DEWA’s shares prior to the dividend record date of 31 March 2025 (
Ecolab Delivers on Commitments to Save Water in Historic AI Era21.3.2025 12:00:00 CET | Press Release
Water is the world’s most essential resource, and it’s only grown more critical in the age of AI. During this transformative digital revolution, Ecolab, a global sustainability leader that maximizes growth and performance through water solutions and infection prevention services, has continued to meet its goals and work with customers to deliver profitability while advancing optimized water use. By 2030, it is estimated that AI-related growth will demand additional power equivalent to the annual needs of India1 and as much water to meet the annual drinking water needs of the United States2. As the world navigates the growth of AI and high-tech data centers, there is a unique opportunity to leverage AI to help drive efficiency and innovation in circular water management to improve operational processes and conserve natural resources. Ecolab’s mission to help protect water while driving business growth is more important than ever. “The rapid acceleration of AI technology is increasing de
Galderma Publishes its 2024 Annual Report and the Invitation to Its First Annual General Meeting21.3.2025 07:00:00 CET | Press Release
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published its 2024 Annual Report along with the invitation to its first Annual General Meeting which will be held on April 23, 2025. Galderma’s 2024 Annual Report, the 2024 Finance Report and the invitation to the Annual General Meeting are available on Galderma’s Investor Relations website at https://investors.galderma.com/. About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals
Almirall's 16 th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology21.3.2025 07:00:00 CET | Press Release
Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice. The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from across the globe to create a network of peers that discuss and learn together to advance the treatment of skin diseases. The event will foster collaboration and co-creation of innovative approaches and solutions to better respond to the unmet needs of the millions of people living with dermatological conditions. Prof. Dr. Ulrich Mrowietz, from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kielin Germany said: "deep collaboration across experts is essential for advanc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom